Diving Into Diabetes

Type 1 Diabetes Screening in the Real World: Tools, Workflows, and Lessons Learned

How can T1D screening programs be effectively established in the clinic, and what are the considerations to get started? Our host, Dr. Alice Cheng, explores this topic with James Stainer, a Registered Nurse and Certified Diabetes Educator at Windsor-Essex Community Health Centre. Join our experts for a foundational discussion detailing the initiation of the first community-based T1D screening program in Canada at Windsor-Essex Community Health Care Centre. Learn about important considerations throughout the planning and screening process including strategies to garner awareness, share results, and facilitate continued monitoring. Hear about how the multidisciplinary screening team collaborates and is setting the stage for additional programs towards the proactive detection of T1D. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Alice Cheng: · Direct financial relationship, including receipt of honoraria: Abbott, Amgen, Astellas, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, MSD, Novo Nordisk, Pfizer, Sandoz, Sanofi, Vertex, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MD Briefcase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, ADA. Membership on advisory boards or speaker’s bureaus: Abbott, Amgen, Astellas, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, MSD, Novo Nordisk, Pfizer, Sandoz, Sanofi, Vertex. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi. James Stainer: · Direct financial relationship, including receipt of honoraria: Sanofi, Dexcom, Abbott, Eli Lilly, Novo Nordisk, Janssen. Membership on advisory boards or speaker’s bureaus: Sanofi, Abbott, Eli Lilly. Funded grants, research, or clinical trials: AstraZeneca. MAT-CA-2600205

Managing diabetes in the elderly: A primary care perspective

How can healthcare providers best navigate the unique complexities of diabetes in an aging population? Our host, Dr. Jeremy Gilbert, explores the multifaceted nature of type 2 diabetes management in the elderly with Dr. Peter Lin, Director of Primary Care Initiatives at the Canadian Heart Research Centre and contributing author to the Diabetes Canada Clinical Practice Guidelines. In this episode, our experts delve into crucial considerations for managing diabetes in older people, including comorbidities, cognition, frailty, hypoglycemia risk, and the use of basal insulins. Hear our experts share their practical strategies for prioritizing care goals, personalizing treatment approaches, fostering multidisciplinary teamwork, and ensuring patient safety and well-being in this vulnerable population. Don’t miss the conversation!  The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.  Declaration of conflict of interest:   Dr. Jeremy Gilbert: * Direct financial relationship, including receipt of honoraria: CPD Network, LMC Canada Inc., CSEM, S&L Solutions, liV Agency, Unik Agency, STA. Membership on advisory boards or speakers’ bureaus: AstraZeneca, Abbott, Amgen, Bayer, Insulet, Tandem, Boehringer Ingelheim, Eli Lilly, GSK, HLS Therapeutics, Novartis, Novo Nordisk, Sanofi. Dr. Peter Lin: * Direct financial relationship, including receipt of honoraria: AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, MDBriefCase, Canadian Heart Research Centre, CCRN, CHIEF, LMC Diabetes & Endocrinology Group, Diabetes Canada, Novo Nordisk, HLS Therapeutics, Medexus Pharmaceuticals, Pri-Med Canada, liV Agency, MEDUCOM Health, The Rounds, Medscape. Membership on advisory boards or speakers’ bureaus: AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, MDBriefCase, Canadian Heart Research Centre, CCRN, CHIEF, LMC Diabetes & Endocrinology Group, Diabetes Canada, Novo Nordisk, HLS Therapeutics, Medexus Pharmaceuticals, Pri-Med Canada, liV Agency, MEDUCOM Health, The Rounds, Medscape. MAT-CA-2500991

Changing the trajectory of T1D with screening and monitoring

How can early identification transform type 1 diabetes (T1D) care and what groundbreaking advances are on the horizon? Our host, Dr. Alice Cheng, explores this topic with Dr. Karen McAssey, a pediatric endocrinologist, researcher, educator, and advocate for people living with T1D at McMaster Children's Hospital in Hamilton, Ontario. Join our experts for a compelling conversation that delves into the profound impact of diabetic ketoacidosis (DKA) and unveils how early intervention can change the course of T1D. Discover why preventing DKA at diagnosis is paramount, learn about the latest consensus guidance for monitoring early-stage T1D, and hear about exciting Canadian research developments shaping the future of T1D screening, monitoring, and prevention. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Alice Cheng: · Direct financial relationship, including receipt of honoraria: Abbott, Amgen, Astellas, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, MSD, Novo Nordisk, Pfizer, Sandoz, Sanofi, Vertex, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MD Briefcase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, ADA. Membership on advisory boards or speaker’s bureaus: Abbott, Amgen, Astellas, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, MSD, Novo Nordisk, Pfizer, Sandoz, Sanofi, Vertex. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi. Dr. Karen McAssey: · Direct financial relationship, including receipt of honoraria: Dexcom, Medtronic, Tandem. Membership on advisory boards or speaker’s bureaus: Abbott, Dexcom, Insulet, Eli Lilly, Medtronic, Sanofi. Funded grants, research, or clinical trials: DRF, NIH-NIDDK, Medtronic. MAT-CA-2500921

Connecting the care team: Optimizing insulin management for diabetes

What are the most effective ways for a diabetes care team to tackle the complexities and challenges of insulin management for patients? Our host, Dr. Alice Cheng, discusses practical approaches in coordinating multidisciplinary diabetes care with Dr. Michelle Long, a Primary Care Physician based in Port Hope, Ontario, with more than 30 years in clinical practice, and Ms. Susie Jin, a Pharmacist and Certified Diabetes Educator based in Cobourg, Ontario, recognized for her national leadership in diabetes. Together, our experts explore the importance of a connected care team—including endocrinologists, general practitioners, pharmacists, and diabetes educators—in optimizing insulin use for patients with diabetes. They discuss strategies for initiating insulin conversations, dispelling misconceptions, and leveraging the expertise of the entire care team. Tune in to hear practical tips for improving communication and collaboration among healthcare providers to better support individuals living with diabetes, especially in resource-limited settings. Don’t miss the conversation!  The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.  Additional resource for healthcare providers: ‘Insulin Pen Start Checklist’ Available at: https://guidelines.diabetes.ca/reduce-complications/insulin-checklist [https://guidelines.diabetes.ca/reduce-complications/insulin-checklist] Declaration of conflict of interest:   Dr. Alice Cheng: * Direct financial relationship, including receipt of honoraria: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MD Briefcase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, ADA. Membership on advisory boards or speaker’s bureaus: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi. Dr. Michelle Long: * None. Ms. Susie Jin: * Direct financial relationship, including receipt of honoraria: Abbott, AbbVie, Boehringer Ingelheim, Dexcom, Sol-M, Canadian Association of Pharmacy Technicians, Canadian Pharmacists Association, Diabetes Canada, Manitoba Pharmacists Association, Ontario Pharmacists Association, Sun Life, Wounds Canada. Membership on advisory boards or speaker’s bureaus: AbbVie, Dexcom, Kenvue, Eli Lilly. Funded grants, research, or clinical trials: Boehringer Ingelheim. MAT-CA-2500670

Type 2 Diabetes: Treatment Priorities in Primary Care

Curious about how primary care practitioners are managing the complexities of type 2 diabetes (T2D) in their practice? Join our host Dr. Alice Cheng as she delves into this topic with Dr. James Kim, Clinical Assistant Professor in the Department of Family Medicine at the University of Calgary, lead editor for the Primary Care section of the Canadian Journal of Diabetes, and a key contributor within Diabetes Canada. Our experts examine the critical role that primary care plays in the early diagnosis of T2D, personalizing and implementing treatment plans, and facilitating regular screening for potential complications. They stress the importance of managing both the physical and mental health of people living with diabetes, and provide practical strategies for organizing care and for maximizing the use of community resources. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Alice Cheng: * Direct financial relationships, including receipt of honoraria: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MDBriefCase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, American Diabetes Association. Membership on advisory boards or speakers’ bureaus: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi. Dr. James Kim: * Direct financial relationships, including receipt of honoraria: Abbott, AbbVie, AstraZeneca, Boehringer Ingelheim, Eisai, embecta, Eli Lilly, GSK, Janssen, Novo Nordisk, Pfizer, Sanofi, Takeda, Searchlight, Otsuka, Teva. Membership of advisory board or speakers’ bureaus: Abbott, AbbVie, ALK, AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, embecta, Eli Lilly, GSK, Novo Nordisk, Sanofi, Teva, Takeda, Searchlight, Valeo. Funded grants, research, or clinical trials: Novo Nordisk. All other investments or relationships: MDBriefCase, CPD Network, Academy for Continued Advancement in Healthcare Education, EOCI, Family Physician Airway Group of Canada, Liv Agency, PPME, CCRN. MAT-CA-2401556